晚期非小细胞肺癌p53 和ERCC1 表达状态与顺铂为主的 联合方案化疗的近期有效率的相关性研究*

目的:研究晚期非小细胞肺癌不同的p53和ERCC1表达状态与基于顺铂为主的姑息化疗近期有效率的相关性。方法:对经顺铂联合多西他赛或顺铂联合吉西他滨治疗的48例晚期非小细胞肺癌患者进行回顾性分析,利用既往免疫组化资料,观察基于顺铂为主的方案近期有效率(RR)的影响因素及化疗不良反应。结果:全组48例患者均完成至少两周期化疗,并行疗效评价。该组患者化疗的近期有效率为28例(58.3%),RR与不同的转移病灶部位(P=0.042)及病灶数目(P=0.034)有显著差异。该类方案的近期有效率与ERCC1状态(P=0.012)密切相关,而与p53表达状态(P=0.401)无关。毒性反应主要是骨髓抑制、脱发及消化道反应等。结论:晚期非小细胞肺癌ERCC1阴性患者较ERCC1阳性患者运用顺铂为主的联合方案化疗的近期有效率较高。ERCC1可能是顺铂疗效预测的敏感因子。p53的表达状态可能不是该类方案的疗效预测因子。

Association of the Advanced Non-Small Cell Lung Cancer p53 and ERCC1 Expression Status with the Short-Term Effect of Combined Chemotherapy Revolved Around Cisplatin

Objective: This study is to explore the correlation of the advanced non-small cell lung cancer p53 and ERCC1 expression status with the Short-term effect of combined chemotherapy revolved around cisplatin.Methods: After cisplatin combined docetaxel or cisplatin combined gemcitabine treatment,48 advanced non-small cell lung cancer patients combined past Immunohistochemical data were analyzed retrospectively.All patients with complete clinical and pathological data were observed as well as the Short-term effect impact factors of the chemotherapy and chemotherapy adverse.Results: The whole group 48 patients have completed at least two cycles of chemotherapy,then completed efficacy evaluation.This group of patients of the chemotherapy recent response rate was 28 cases(58.3%),RR with different metastatic sites(P=0.042) and the number of Metastasis(P = 0.028) were significantly different.The chemotherapy Short-term effect is closely related with ERCC1 expression status(P=0.034)and not with p53 expression status(P=0.401).Mainly toxicity symptoms were arrest of bone marrow,losing hair and archenteric indisposed.Conclusions: Advanced non-small cell lung cancer patients with ERCC1-negative have more effective Short-term effect of combined chemotherapy revolved around cisplatin than ERCC1-positive patients.ERCC1 may predict the efficacy of cisplatin-sensitive factor.The expression of p53 may not be predictors of the efficacy of cisplatin.